Human Metabolome Technologies (TSE:6090) Piotroski F-Score: 3 (As of Jul. 12, 2026) — 25% Below Median


TSE:6090 Human Metabolome Technologies Inc TSE:6090
59 GF Score
Price 円598.00
GF Value 円529.55
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Human Metabolome Technologies Piotroski F-Score?

Human Metabolome Technologies TSE:6090 +0.84% 59 Piotroski F-Score is 3 as of Jul. 12, 2026, which is 25% below its 10-year median of 4.00. GuruFocus rates TSE:6090 with a GF Score™ of 59/100 and a GF Value™ of 円529.55 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 210 Medical Diagnostics & Research companies, Human Metabolome Technologies ranks worse than 73.33% on this metric.

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Human Metabolome Technologies has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Human Metabolome Technologies's Piotroski F-Score or its related term are showing as below:

TSE:6090' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 4   Max: 7
Current: 3

During the past 12 years, the highest Piotroski F-Score of Human Metabolome Technologies was 7. The lowest was 1. And the median was 4.

Human Metabolome Technologies  (TSE:6090) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Human Metabolome Technologies Piotroski F-Score Related Terms


Human Metabolome Technologies Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Human Metabolome Technologies's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Human Metabolome Technologies Piotroski F-Score Chart

Human Metabolome Technologies Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Jun20 Jun21 Jun22 Jun23 Jun24
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 3.00 7.00 4.00 3.00

Human Metabolome Technologies Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 6.00 0.00 0.00 0.00

TSE:6090 vs TMO, DHR, IDXX: Piotroski F-Score Comparison

For the Diagnostics & Research subindustry, Human Metabolome Technologies's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Human Metabolome Technologies Piotroski F-Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Human Metabolome Technologies's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Human Metabolome Technologies's Piotroski F-Score falls into.


TSE:6090
59GF Score
Human Metabolome Technologies Inc TSE:6090
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun24) TTM:Last Year (Jun23) TTM:
Net Income was 円243.2 Mil.
Cash Flow from Operations was 円236.8 Mil.
Revenue was 円1,345.7 Mil.
Gross Profit was 円869.3 Mil.
Average Total Assets from the begining of this year (Jun23)
to the end of this year (Jun24) was (2291.058 + 2603.401) / 2 = 円2447.2295 Mil.
Total Assets at the begining of this year (Jun23) was 円2,291.1 Mil.
Long-Term Debt & Capital Lease Obligation was 円11.3 Mil.
Total Current Assets was 円2,095.6 Mil.
Total Current Liabilities was 円632.8 Mil.
Net Income was 円285.8 Mil.

Revenue was 円1,299.2 Mil.
Gross Profit was 円859.8 Mil.
Average Total Assets from the begining of last year (Jun22)
to the end of last year (Jun23) was (2068.728 + 2291.058) / 2 = 円2179.893 Mil.
Total Assets at the begining of last year (Jun22) was 円2,068.7 Mil.
Long-Term Debt & Capital Lease Obligation was 円13.2 Mil.
Total Current Assets was 円1,848.3 Mil.
Total Current Liabilities was 円493.0 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Human Metabolome Technologies's current Net Income (TTM) was 243.2. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Human Metabolome Technologies's current Cash Flow from Operations (TTM) was 236.8. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun23)
=243.248/2291.058
=0.10617278

ROA (Last Year)=Net Income/Total Assets (Jun22)
=285.758/2068.728
=0.13813222

Human Metabolome Technologies's return on assets of this year was 0.10617278. Human Metabolome Technologies's return on assets of last year was 0.13813222. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Human Metabolome Technologies's current Net Income (TTM) was 243.2. Human Metabolome Technologies's current Cash Flow from Operations (TTM) was 236.8. ==> 236.8 <= 243.2 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun23 to Jun24
=11.344/2447.2295
=0.00463545

Gearing (Last Year: Jun23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun22 to Jun23
=13.16/2179.893
=0.00603699

Human Metabolome Technologies's gearing of this year was 0.00463545. Human Metabolome Technologies's gearing of last year was 0.00603699. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun24)=Total Current Assets/Total Current Liabilities
=2095.627/632.757
=3.31189856

Current Ratio (Last Year: Jun23)=Total Current Assets/Total Current Liabilities
=1848.331/493.007
=3.74909687

Human Metabolome Technologies's current ratio of this year was 3.31189856. Human Metabolome Technologies's current ratio of last year was 3.74909687. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Human Metabolome Technologies's number of shares in issue this year was 5.913. Human Metabolome Technologies's number of shares in issue last year was 5.905. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=869.331/1345.671
=0.64602046

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=859.752/1299.225
=0.66174219

Human Metabolome Technologies's gross margin of this year was 0.64602046. Human Metabolome Technologies's gross margin of last year was 0.66174219. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun23)
=1345.671/2291.058
=0.58735789

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun22)
=1299.225/2068.728
=0.62803085

Human Metabolome Technologies's asset turnover of this year was 0.58735789. Human Metabolome Technologies's asset turnover of last year was 0.62803085. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+0+1+0+0+0+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Human Metabolome Technologies has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 3 mean?
Human Metabolome Technologies (TSE:6090) has a Piotroski F-Score of 3 as of Jul. 12, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Human Metabolome Technologies and its competitors. This is 25% below median its historical median of 4.00. Over the past decade, Human Metabolome Technologies' Piotroski F-Score has ranged from 1.00 to 7.00. According to the industry distribution chart, Human Metabolome Technologies ranks #154 out of 210 companies in the Medical Diagnostics & Research industry, placing it in the top 73.3%.
Is Human Metabolome Technologies' Piotroski F-Score too high?
Human Metabolome Technologies' current Piotroski F-Score of 3 is 25% below median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 7.00. The Medical Diagnostics & Research industry median Piotroski F-Score is 5.00. Human Metabolome Technologies' value of 3 is 40% below this industry median. Based on the distribution chart, Human Metabolome Technologies ranks #154 out of 210 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Human Metabolome Technologies has a GF Score™ of 59/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Human Metabolome Technologies' Piotroski F-Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Human Metabolome Technologies ranks #154 out of 210 companies for Piotroski F-Score. This places Human Metabolome Technologies in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Human Metabolome Technologies' value of 3 is 40% below this benchmark. Historically, Human Metabolome Technologies' own Piotroski F-Score has ranged from 1.00 to 7.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 5.00, Human Metabolome Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Diagnostics & Research company?
The median Piotroski F-Score among Medical Diagnostics & Research companies is 5.00, based on 210 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Human Metabolome Technologies's current Piotroski F-Score of 3 is 40% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Human Metabolome Technologies and its competitors. For the Medical Diagnostics & Research industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Human Metabolome Technologies's current Piotroski F-Score is 3, which is 25% below median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Human Metabolome Technologies stock overvalued right now?
Based on GuruFocus' analysis, Human Metabolome Technologies (TSE:6090) is currently considered Modestly Overvalued. The stock's GF Value™ is 円529.55, compared to a current price of 円598.00 — trading 12.9% above its estimated fair value. The current Piotroski F-Score is 3, which is 25% below median its 10-year median of 4.00 and 40% below the Medical Diagnostics & Research industry median of 5.00. Human Metabolome Technologies' overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Human Metabolome Technologies (TSE:6090), the current Piotroski F-Score is 3 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Human Metabolome Technologies (TSE:6090) Overvalued in 2026?

Based on GuruFocus' analysis, Human Metabolome Technologies stock appears to be overvalued. The current stock price of 円598.00 is trading 12.9% above its estimated GF Value™ of 円529.55. GuruFocus considers Human Metabolome Technologies to be Modestly Overvalued.

Key valuation signals for TSE:6090:

  • Piotroski F-Score: 3 (25% below median its 10-year median of 4.00)
  • GF Value™: 円529.55 vs. price of 円598.00 (12.9% above fair value)
  • GF Score™: 59/100 with 4 warning signs
  • Industry Position: 40% below the Medical Diagnostics & Research median (#154 of 210)

No single metric tells the full story. See the TSE:6090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Human Metabolome Technologies Business Description

Address Yamagata Prefecture Kakuganji Water 246-2, Tsuruoka, JPN, 997-0052
Human Metabolome Technologies Inc is involved in the search and diagnosis of biomarkers and commercialization in the field of drug development.
59GF Score

Get the complete analysis for TSE:6090

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円598.00
Price
円529.55
GF Value